TrialThe AAPS journal2011
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
Dinko Rekić et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled ittrialcites it